To fight cancer, you need to stop cancerous cells from growing.
The scientists behind Faeth Therapeutics Inc. have some new ideas about how to do that. The San Francisco company now has $20 million in seed funding to develop those ideas.
"We're using precision therapies, software and nutrition to help treat cancer, for the millions of patients who desperately need better
outcomes," Anand Parikh, Faeth's CEO and co-founder, said in a press release announcing its new funding round.
Faeth's scientists have focused in part on using food to combat cancer. The company uses machine learning to analyze the dietary needs of cancerous tumors. It then crafts a diet for patients that's designed to help starve their particular cancers.
Faeth is also developing a drug that can inhibit the proliferation of enzymes that help cancer cells grow. The drug, dubbed Serabelisb, will undergo clinical trials this year it said.
Here's more on Faeth's round and other seed funding news from the last week:
Faeth Therapeutics Inc., San Francisco, $20 million: Khosla Ventures and Future Ventures co-led the round for this developer of cancer treatments including a nutritional program designed to help slow the growth of tumors. S2G Ventures, Digitalis, KdT Ventures, Agfunder, Cantos and Unshackled also invested.
Permiso Security Inc., Palo Alto, $10 million: Point72 Ventures led the round for this developer of cloud security software. Foundation Capital, Work-Bench, 11.2 Capital and Rain Capital also invested.
Paysail Inc., San Francisco, $4 million: Uncork Capital led the round for this provider of an invoicing and payments service for businesses that's built around reputedly stable cryptocurrencies. Tribe Capital, Pear VC and Mischief Capital also invested.
